



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Ingraham, R. H. et al ) Art Unit: 1626  
U.S. Appln. No. : 10/670,668 ) Examiner: Shameem, G.M.  
U.S. Filing Date : September 25, 2003  
Confirmation No. : 1467  
Title of Invention : Methods of Using Soluble Hydroxide Hydrolase Inhibitors  
Attny. Docket No. : 9/213-1-C1

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

May 17, 2004

TRANSMITTAL LETTER FOR SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

☒ 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

☐ A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).

☐ 1.97(e).

☐ Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or

☐ No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,




Anthony P. Bottino  
Attorney for Applicant(s)  
Reg. No. 41,629

Patent Department  
Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 791-6764

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE WITH SUFFICIENT POSTAGE FOR FIRST  
CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE

Mail Stop Amendment  
COMMISSIONER FOR PATENTS,  
P.O. Box 1450  
Alexandria, VA 22313-1450



By: Anthony P. Bottino  
Reg. No. . 41,629



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

### Complete If Known

|                        |                      |
|------------------------|----------------------|
| Application Number     | 10/670,668           |
| Filing Date            | September 25, 2003   |
| First Named Inventor   | Ingraham, R.H. et al |
| Art Unit               | 1626                 |
| Examiner Name          | Shameem, G.M.        |
| Attorney Docket Number | 9/213-1-C1           |

### NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|-----------------------|--------------------------|---|----------------|
|                       |                          | James M. TREVILLYAN, et al; Potent Inhibition of NFAT Activation and T Cell Cytokine Production by Novel Low Molecular Weight Pyrazole Compounds, Journal of Biological Chemistry, Vol. 276, No. 51 pp. 48118-48126, 2001                                       |                |
|                       |                          | Christof ZITT, et al; Potent Inhibition of Ca2+ Release-activated Ca2+ Channels and T-lymphocyte Activation by the Pyrazole Derivative BTP2*, Journal of Biological Chemistry, Vol. 279, No. 13, Issue of March 26, pp12427-12437, 2004                         |                |
|                       |                          | Jun ISHIKAWA, et al; A Pyrazole Derivative, YM-58483, Potently Inhibits Store-Operated Sustained Ca2+ Influx and IL-2 Production in T Lymphocytes, The Journal of Immunology pp. 4441-4449  |                |
|                       |                          | Steven DJURIC, et al; 3-5 Bis(trifluoromethyl)pyrazoles: A Novel Class of NFAT Transcription Factor Regulator, Journal of Med. Chem. 2000, 43, 2975-2981  |                |
|                       |                          | Yung-Wu CHEN, et al; TH1 and TH2 cytokine inhibition by 3-5 Bis(trifluoromethyl) pyrazoles, a novel class of immunomodulators, Cellular Immunology 220 (2002) 134-142   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.